Tenderwize
Zurück zur Suche

Medicinal products with the active substance Erythropoietin (ATC: B03XA01 - in strength up to 10,000 IU per dose unit)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Aug 30, 2026 · 4 days left·Open·Supplies
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Erythropoietin (ATC: B03XA01 - in der Wirkstärke bis 10.000 IE je Dosiereinheit)

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

50 / 100

Komplexität

30 / 100

Risikofaktoren

Buyer may terminate contracts early if exclusive contracts are awarded later; no compensation mentioned.

No estimated value; revenue potential is uncertain.

Submission deadline in 4 days

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Non-exclusive discount agreements for erythropoietin medications (ATC B03XA01, strength up to 10,000 IU per dose unit)
  • Open-house model with continuous application possibility
Vollständige Zusammenfassung anzeigen

This is an open-house model for non-exclusive discount agreements under German social law (§130a SGB V) for erythropoietin medications (ATC B03XA01, strength up to 10,000 IU per dose unit). The buyer is AOK Sachsen-Anhalt. There is no competitive award; any eligible pharmaceutical company can join. The contract duration is up to 24 months (01.11.2024 to 31.10.2026). No estimated value is provided. The notice is published for transparency only and explicitly states it is not a public procurement.

Risiken

Buyer may terminate contracts early if exclusive contracts are awarded later; no compensation mentioned.

No estimated value; revenue potential is uncertain.

Submission deadline in 4 days

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical company or consortium of pharmaceutical companies
  • Must comply with standard contract conditions

Administrative

  • Must request and submit participation documents completely and signed

Anforderungen können unvollständig sein.

Zuschlagskriterien

Lot 1

Open-house: no competitive award; all eligible companies are accepted.

Auftraggeber

Ort

Magdeburg, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE258393558

Tätigkeit

Health

Lose (1)

LOT-0001

Medicinal products with the active substance Erythropoietin (ATC: B03XA01 - in strength up to 10,000 IU per dose unit)

Non-exclusive discount agreements for erythropoietin medications under an open-house model. Any eligible pharmaceutical company can conclude a contract at any time. Contract duration up to 24 months, ending 31.10.2026 regardless of start date.

SuppliesEU fundedElectronic submission

Ort

DEE03, Germany

Dauer

2 YEAR

Kategorie

Pharmaceutical products

Zuschlagskriterien

Open-house: no competitive award; all eligible companies are accepted.

Frist

Deadline Aug 31, 2026

Vergabedetails

Veröffentlichungsdatum
19 Sep 2024
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
566953-2024

Dokumente (1)

Ähnliche Ausschreibungen